NASDAQ:JYNT Joint (JYNT) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free JYNT Stock Alerts $12.28 -0.31 (-2.46%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$12.12▼$12.5850-Day Range$9.14▼$13.0952-Week Range$7.31▼$16.48Volume39,224 shsAverage Volume90,195 shsMarket Capitalization$183.41 millionP/E RatioN/ADividend YieldN/APrice Target$21.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Joint alerts: Email Address Joint MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside75.1% Upside$21.50 Price TargetShort InterestHealthy5.23% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.21Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth284.62%From $0.13 to $0.50 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.64 out of 5 starsMedical Sector432nd out of 909 stocksPatent Owners & Lessors Industry4th out of 6 stocks 3.2 Analyst's Opinion Consensus RatingJoint has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageJoint has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.23% of the outstanding shares of Joint have been sold short.Short Interest Ratio / Days to CoverJoint has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Joint has recently decreased by 7.71%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldJoint does not currently pay a dividend.Dividend GrowthJoint does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for JYNT. Previous Next 1.8 News and Social Media Coverage News SentimentJoint has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Joint this week, compared to 2 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Joint insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.00% of the stock of Joint is held by insiders.Percentage Held by Institutions76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Joint are expected to grow by 284.62% in the coming year, from $0.13 to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Joint is -18.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Joint is -18.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJoint has a P/B Ratio of 7.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Joint Stock (NASDAQ:JYNT)The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.Read More JYNT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JYNT Stock News HeadlinesApril 20, 2024 | seekingalpha.comThe Joint Corp. Switches Its Focus To ProfitabilityApril 18, 2024 | finance.yahoo.comThe Joint Corp. to Host Conference Call on Thursday, May 2nd to Discuss First Quarter 2024 ResultsApril 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 18, 2024 | globenewswire.comThe Joint Corp. to Host Conference Call on Thursday, May 2nd to Discuss First Quarter 2024 ResultsApril 18, 2024 | americanbankingnews.comJoint (NASDAQ:JYNT) Stock Price Passes Above Fifty Day Moving Average of $11.48April 17, 2024 | finance.yahoo.comThe Joint Chiropractic Proudly Supports Colorado-Based Rachel's ChallengeApril 17, 2024 | prnewswire.comThe Joint Chiropractic Proudly Supports Colorado-Based Rachel's ChallengeApril 17, 2024 | finance.yahoo.comThe Joint Corp. (JYNT)April 24, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinApril 2, 2024 | prnewswire.comLogan University Establishes The Joint Chiropractic Endowed ScholarshipMarch 12, 2024 | markets.businessinsider.comOn Holding Posts Adj. Loss In Q4 - Quick FactsMarch 9, 2024 | finance.yahoo.comEarnings Miss: The Joint Corp. Missed EPS And Analysts Are Revising Their ForecastsMarch 8, 2024 | finance.yahoo.comThe Joint Corp. (NASDAQ:JYNT) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comThe Joint Corp (JYNT) Faces Net Loss in 2023 Despite Revenue GrowthMarch 8, 2024 | investorplace.comJYNT Stock Earnings: Joint Misses EPS, Beats Revenue for Q4 2023March 7, 2024 | msn.comJoint GAAP EPS of -$0.75 misses by $0.76, revenue of $30.6M beats by $1.52MMarch 7, 2024 | globenewswire.comThe Joint Corp. Reports Fourth Quarter and Year-end 2023 Financial ResultsMarch 6, 2024 | seekingalpha.comJoint Q4 2023 Earnings PreviewMarch 4, 2024 | finance.yahoo.comThe Joint Corp. to Participate in the 36th Annual Roth ConferenceMarch 4, 2024 | globenewswire.comThe Joint Corp. to Participate in the 36th Annual Roth ConferenceMarch 2, 2024 | usatoday.comBest joint personal loans of February 2024February 22, 2024 | finance.yahoo.comThe Joint Corp. to Host Conference Call on Thursday, March 7th to Discuss Fourth Quarter and Year-end 2023 ResultsFebruary 22, 2024 | globenewswire.comThe Joint Corp. to Host Conference Call on Thursday, March 7th to Discuss Fourth Quarter and Year-end 2023 ResultsFebruary 15, 2024 | uk.investing.comThe Joint Corp (JYNT)January 24, 2024 | finance.yahoo.comThe Joint Chiropractic Named No. 1 in Chiropractic Services, Ranked Among Top Franchises in Entrepreneur Magazine's Franchise 500January 15, 2024 | finance.yahoo.comWith 51% ownership of the shares, The Joint Corp. (NASDAQ:JYNT) is heavily dominated by institutional ownersJanuary 11, 2024 | msn.comThe Joint reports growth in 2023 operating metrics below 2022 levelSee More Headlines Receive JYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today4/24/2024Next Earnings (Confirmed)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Patent owners & lessors Sub-IndustryN/A Current SymbolNASDAQ:JYNT CUSIPN/A CIK1612630 Webwww.thejoint.com Phone(480) 245-5960Fax480-513-7989Employees444Year FoundedN/APrice Target and Rating Average Stock Price Target$21.50 High Stock Price Target$30.00 Low Stock Price Target$13.00 Potential Upside/Downside+70.8%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E Ratio96.85 P/E GrowthN/ANet Income$-9,750,000.00 Net Margins-8.19% Pretax Margin1.39% Return on Equity7.80% Return on Assets2.65% Debt Debt-to-Equity Ratio0.08 Current Ratio1.32 Quick Ratio1.32 Sales & Book Value Annual Sales$117.70 million Price / Sales1.58 Cash Flow$0.75 per share Price / Cash Flow16.78 Book Value$1.68 per share Price / Book7.49Miscellaneous Outstanding Shares14,780,000Free Float14,185,000Market Cap$186.08 million OptionableOptionable Beta1.59 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesMr. Peter D. Holt (Age 65)CEO, President & Director Comp: $469.55kJake Singleton (Age 42)Chief Financial Officer Comp: $280.92kMr. Jorge ArmenterosSenior Vice President of OperationsMr. Charles NellesChief Technology OfficerDr. Steven KnaufVice President of Chiropractic & ComplianceMs. Lori I. Abou Habib (Age 44)Chief Marketing Officer Ms. Krischelle TennessenChief Human Resources OfficerMr. Eric SimonSenior VP of Franchise Sales & DevelopmentMr. Craig P. Colmar J.D. (Age 71)Secretary Comp: $37kMore ExecutivesKey CompetitorsCardiff OncologyNASDAQ:CRDFVeruNASDAQ:VERUAtossa TherapeuticsNASDAQ:ATOSAkoya BiosciencesNASDAQ:AKYAINmune BioNASDAQ:INMBView All CompetitorsInsiders & InstitutionsBridge City Capital LLCBought 9,492 shares on 4/12/2024Ownership: 0.150%Avondale Wealth ManagementBought 12,500 shares on 4/2/2024Ownership: 0.129%Sierra Summit Advisors LLCBought 67,857 shares on 2/22/2024Ownership: 0.460%Corsair Capital Management L.P.Bought 25,851 shares on 2/14/2024Ownership: 0.175%Bard Associates Inc.Bought 3,250 shares on 2/13/2024Ownership: 0.539%View All Insider TransactionsView All Institutional Transactions JYNT Stock Analysis - Frequently Asked Questions Should I buy or sell Joint stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Joint in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" JYNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in JYNT, but not buy additional shares or sell existing shares. View JYNT analyst ratings or view top-rated stocks. What is Joint's stock price target for 2024? 3 Wall Street analysts have issued 1 year price objectives for Joint's stock. Their JYNT share price targets range from $13.00 to $30.00. On average, they anticipate the company's share price to reach $21.50 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price. View analysts price targets for JYNT or view top-rated stocks among Wall Street analysts. How have JYNT shares performed in 2024? Joint's stock was trading at $9.61 at the beginning of 2024. Since then, JYNT stock has increased by 27.8% and is now trading at $12.28. View the best growth stocks for 2024 here. When is Joint's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our JYNT earnings forecast. How can I listen to Joint's earnings call? Joint will be holding an earnings conference call on Thursday, May 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "8179924". How were Joint's earnings last quarter? The Joint Corp. (NASDAQ:JYNT) issued its quarterly earnings results on Thursday, March, 7th. The company reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.03 by $0.04. The firm had revenue of $30.61 million for the quarter, compared to analyst estimates of $29.63 million. Joint had a positive trailing twelve-month return on equity of 7.80% and a negative net margin of 8.19%. What is Peter D. Holt's approval rating as Joint's CEO? 87 employees have rated Joint Chief Executive Officer Peter D. Holt on Glassdoor.com. Peter D. Holt has an approval rating of 59% among the company's employees. This puts Peter D. Holt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Joint own? Based on aggregate information from My MarketBeat watchlists, some companies that other Joint investors own include Advanced Micro Devices (AMD), RTX (RTX), Salesforce (CRM), Mastercard (MA), Starbucks (SBUX), Twitter (TWTR), Viking Therapeutics (VKTX), AbbVie (ABBV) and Adobe (ADBE). When did Joint IPO? Joint (JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.50 per share. Roth Capital Partners and Feltl and Company acted as the underwriters for the IPO and Sanders Morris Harris was co-manager. Who are Joint's major shareholders? Joint's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Bridge City Capital LLC (0.15%) and Avondale Wealth Management (0.13%). Insiders that own company stock include Bandera Partners Llc, Glenn J Krevlin, Jake Singleton, James H Amos Jr, Matthew E Rubel, Matthew E Rubel, Peter D Holt and Ronald V Davella. View institutional ownership trends. How do I buy shares of Joint? Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:JYNT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding The Joint Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
